Objective: To explore the value of nuclear magnetic resonance (NMR) and functional assessments for follow-up of ambulatory and nonambulatory patients with Duchenne muscular dystrophy (DMD).
Results: Upper limb distal strength decreased in nonambulatory patients over the period of 1 year; ambulatory patients showed improvement during the same period. The same applied for several NMRS indices, such as phosphocreatine/adenosine triphosphate, which decreased in older patients but increased in younger ambulatory patients. Fat infiltration in the upper limbs increased linearly with age. Almost all NMR and functional assessment results correlated.
Conclusions:
Our results underscore complementarity of functional and NMR assessments in patients with DMD. Sensitivity to change of various indices may differ according to disease stage.
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As therapeutic strategies are developed in Duchenne muscular dystrophy (DMD), the need for robust outcome measures to assess the effects of these interventions through the different stages of the disease is increasingly crucial. Currently, the 6-Minute Walk Test (6MWT) is the most commonly used primary outcome measure for assessing the efficacy of therapeutic agents. Therefore, most clinical drug studies are conducted in ambulatory patients. The extension of efficacy data to nonambulatory patients, in whom muscular tissue is more damaged, remains challenging. Given the potential side effects and the very high cost of innovative therapies, evaluation of efficacy in nonambulatory patients is essential.
New upper limb muscle strength and motor ability assessments have recently been developed. [1] [2] [3] [4] [5] [6] Other approaches to define surrogate endpoints, such as biomarkers or nuclear magnetic resonance (NMR) imaging (NMRI) and spectroscopy (NMRS), have also been described. Resting-state NMR is equally valuable in examination of upper and lower limbs. Despite pioneering NMRS work in forearm muscles of patients with DMD, 7 NMR data have since been primarily acquired in pelvic muscles or lower limbs in ambulant patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We recently reported the feasibility of using NMR for assessing the upper limb in nonambulatory patients. 21 Our main objective in the present study was to establish the baseline values for NMR and functional variables and at a 1-year follow-up time point period for ambulatory and nonambulatory patients with DMD. Secondary aims were to explore the possible relationships between functional and NMR variables and their respective and complementary responsiveness to disease evolution over time.
METHODS Participants and study design. Within the framework of a large gene therapy program, and with the ultimate aim of initiating a phase I-II adeno-associated virus 8-U7 clinical trial, 22 we launched a natural history study of patients potentially eligible for treatment by induction of skipping of exon 53 of the dystrophin gene, in order to establish long-term pretreatment values in patients with DMD who are likely to take part in the protocol. The main inclusion criteria were the following: confirmation of a mutation theoretically treatable by exon 53 skipping, aged between 6 and 20 years, and weight above 15 kg. Exclusion criteria were the following: inability to sit upright in a wheelchair for at least 1 hour, severe intellectual impairment preventing full understanding of tests, recent upper limb surgery or trauma, or known immunodeficiency. All patients underwent clinical and functional assessments every 6 months using the Motor Function Measure (MFM; http://www.motor-functionmeasure.org) and the MyoSet devices specifically developed and validated for weak patients 4, 5, 23 (MyoGrip and MyoPinch for hand grip and key pinch strength and MoviPlate for function). Patients were assessed by NMRS and NMRI annually. The duration of the study is planned for 4 years. Here we report the results of the first year (3 visits).
Standard protocol approvals, registrations, and patient consents. All patients (or legal guardians for patients younger than 18 years) gave written informed consent prior to participation in this study. The local ethics committee approved the study protocol (CPP-Ile de France VI; La Pitié-Salpêtrière, protocol 88-10; clinicaltrials. gov, NCT01385917). Patients were invited to participate through the French Registry for DMD and collaborating neuromuscular centers in Belgium, Switzerland, and Romania.
Strength and functional assessments. Assessments took place in a quiet muscle evaluation laboratory. We performed tests with patients seated on a chair or in their wheelchair facing a heightadjustable table with their forearm placed on the table or on the wheelchair tray. Before each test, we described the task to patients, demonstrated the movement required, and instructed the patient on maintaining correct practice. If standard upper limb position prescribed by the protocol could not be maintained because of patient contractures, an alternative position was allowed. The patients performed strength tests and then functional tests.
For the MyoSet tests, at least 2 attempts were recorded for each tool and side. We conducted a third and possibly fourth trial if the score for the second attempt was higher than that of the first one, or if the difference between trials was greater than 10%. We used a dedicated custom-made quality control software program to record signals generated using MyoGrip, MyoPinch, and Mo-viPlate. The side chosen to be tested first was based upon whether the patient had an even or odd patient registry number. We defined the dominant hand as the hand that the patient wrote with (or the one with which the patient previously wrote) and used verbal encouragement when conducting MyoSet. Patients were given a 1-minute rest period between trials for the same device and a 3-minute rest period when changing devices. NMRI/NMRS acquisitions. Patient examinations took place in a 3T-60 cm Siemens (Munich, Germany) TRIO with the arm resting alongside the body, as previously detailed. 21 We examined each arm in separate sessions on the same day and repeated the examinations 1 year later. Each session consisted of quantitative NMRI and phosphorous NMRS, each lasting approximately 20 minutes, with the patient repositioned between the 2 examinations. We acquired quantitative NMRI measurements of (1) muscle water relaxation time T2 in 3 slices in the forearm (echo times 8.7-147.9 ms, repetition time [TR] 4 seconds, field of view 104 3 128 mm 2 ); (2) fat fraction by 3D, 3point Dixon imaging covering the same regions, TR 10 ms, 166 3 480 3 128 mm 3 ; and (3) phosphorous NMRS to measure phosphate metabolites using an 11-cm-diameter surface coil predominantly facing flexor muscles (nonlocalized, 500 ms hard pulse excitation [TR 4 seconds, number of excitations 64-128, bandwidth 5 3,000 Hz]).
We used 3 NMRI indices in the study: % fat signal (%F), muscle water T2, deconvoluted from fat, 24 and T2 heterogeneity (coefficient of variation in a region of interest comprising all flexor muscles of the forearm). We also used 7 NMRS indices: the weighted average pH and 6 metabolic ratios combining adenosine triphosphate (ATP), phosphocreatine (PCr), phosphomonoesters (PME) and phosphodiesters (PDE), and 2 pools of inorganic phosphate (cytosolic [Pia] and an anomalous alkaline pool present in dystrophic muscle [Pib]). 25 Statistical analyses. We used nonparametric tests for analysis of non-Gaussian distribution of most variables and classified patients at inclusion according to ambulation status. We classified ambulatory patients as having the ability to walk 10 meters independently without technical or human aid. Descriptive statistics are presented for both groups of patients as median and first and third quartiles of the distribution of the variables (Q1; Q3). We pooled data from dominant and nondominant sides because differences between sides were not statistically different in 12 of 14 variables (tested with a Wilcoxon test). We tested 1-year differences using a Wilcoxon test. We tested for differences between variables from ambulatory and nonambulatory patients at inclusion using a Mann-Whitney test. For correlation analyses between variables, we treated data from V1 and V3 and dominant and nondominant sides as independent observations and Spearman rho correlation coefficients were computed. We did not perform a statistical analysis to check for the effect of steroids on the various outcome measures as steroid users were not evenly distributed over the various ages of the patients: the large majority of the steroid users were young ambulatory patients. We conducted all analyses using SPSS v.19 statistical software (SPSS Inc., Chicago, IL, USA). A p , 0.05 was considered significant.
RESULTS Population description. Twenty-five patients with DMD were included in the study; 15 were nonambulatory at baseline. One patient became nonambulatory between the first and second visits. Characteristics of both ambulant and nonambulant groups are presented in table 1. We observed 6 different deletions in the dystrophin gene among the patients (del45-52 in 8 patients, del47-52 in 1 patient, del48-52 in 5 patients, del49-52 in 3 patients, del50-52 in 5 patients, del52 in 3 patients).
Baseline data. Data for functional and NMR variables at baseline are presented in table 1 for both patient groups. Most variables differed between ambulatory and nonambulatory patients, underlining the more severe phenotype of the latter. Hand grip strength, pinch strength, and MFM scores (and each of its dimensions) decreased with increasing age (all p , 0.001) (figure 1). This was not the case for the Mo-viPlate results (p 5 0.670), which decreased only for the oldest and therefore weakest patients. One nonambulatory patient who showed more preserved strength relative to his age was considered an outlier. All selected NMR variables except Pi/ATP also correlated with age with rho values ranging from 0.237 (p 5 0.038) for Pia/PCr to 0.746 (p , 0.001) for %F; T2 (rho 5 0.457; p , 0.001) showed normalization with increasing age, but all other measures worsened, as reported previously. 21 Changes over 1 year. Changes over 1 year contrasted between ambulatory and nonambulatory patients (table 2) . For instance, in functional upper limb measurements, ambulatory patients showed improved Mo-viPlate performance score and no change in grip and pinch, while nonambulatory patients showed a loss of (table 3) . Most correlations were not linear. Figure 2 illustrates the relationships between grip strength and selected NMR variables, as measured in the flexor muscles of the forearm, and demonstrates the sensitivity of the various indices to disease stage. The patient, noted above as an outlier for functional performance, fell within the correlation curve with regard to NMR variables. DISCUSSION In this longitudinal study, we assessed and analyzed upper limb function and strength of patients with DMD using both functional tests and NMRI and NMRS. We have followed ambulatory and nonambulatory patients over a 1-year period in a study planned to last 4 years. We demonstrated that evolution of the disease as monitored by NMR and functional assessments of the upper limb is very different in nonambulatory and in ambulatory patients; the exception is %F, which increased as disease progressed.
One strength of this study is its inclusion as part of gene therapy program; data collection was strictly controlled and monitored, and the same evaluators performed all data acquisition and analysis. In addition, the study evaluated a relatively homogenous population from a genetic point of view, since all patients present with deletions potentially treatable by induction of skipping of exon 53 of the dystrophin gene. One limitation is potential generalization of such results to the overall DMD population. Although patients potentially treatable by exon 53 skipping tend to have more severe symptoms than the overall DMD population, 26 evolution over a 1-year period is similar to that of the general DMD population (data not shown). Several possible reasons could underlie the more severe phenotype of these patients: they may be smaller in stature compared to other patients with DMD, may have a smaller number of revertant fibers, and may have a weaker response to steroids. These assumptions need to be explored further. DMD is characterized by a progressive loss of muscle fibers, which are gradually replaced by fat and connective tissue. The disease typically develops from proximal to more distal muscles. Muscles of the hands are thus less affected throughout the disease course. 27 Few studies have focused on the upper limbs of patients with DMD, despite the importance of maintaining functional independence as long as possible. 28 Grip and pinch strength correlate with physical disability in patients with DMD older than 10 years. 5, 27 Before 10 years of age, growth and maturation seem to partly compensate for disease progression, 27 as depicted here by an improvement in both strength (grip and pinch) and function (MoviPlate) of ambulatory patients over the 1-year observation period. The increase in MoviPlate score in younger nonambulatory patients, as previously reported, 4 suggests that compensation strategies are still developing at this stage, until the weakness overrides the potential for adaptation. A possible training effect cannot be ruled out, however. One method to minimize the confounding factors of growth and maturation would be to express strength values as a percentage of predicted values based on normative data. Stature is a major predictive factor of muscle strength, 29 but methods for an accurate estimate of stature may be challenging because height or femur length may not be easy to obtain in nonambulatory or retracted patients. This is not the case with hand circumference, which can be easily measured and which has been shown to provide a good estimate of stature and a good prediction of grip strength. 30 Strength normalized by stature could be used in the future to provide markers of disease activity that are independent of growth and maturation. Similarly, in NMR evaluations, PCr/ATP increased in ambulatory patients, corresponding to a likely maturation process, but decreased in nonambulatory patients, especially in the older patients, corresponding to loss of metabolically active tissue. 21 Various NMR indices reflect different aspects of muscle anomalies and their interpretation has been detailed in a dog model of DMD. 25, 31 Overall, NMR alterations observed here in the upper limb of patients correlated with those observed in the lower limbs of younger patients. Fat infiltration correlated with clinical assessments such as timed walking/running or rising from supine tests, manual muscle testing, MFM, or Brooke scales. 8, 9, [11] [12] [13] 15, 19, 20, 32, 33 %F in lower limb has been reported previously to be predictive of ambulation loss and linearly correlated with MFM 9 and strength, 19 whereas metabolic factors did not correlate linearly. We reproduced these findings in upper limbs of nonambulatory patients. A likely explanation is that %F increases linearly with age, whereas many of the metabolic NMR measures evolve principally at a more specific stage of disease according to the different muscle groups. This particular issue needs further investigation.
T2 of muscle water reflects inflammation, edema, or the presence of cell lesions and increases in dystrophic muscle. 31, [34] [35] [36] It does not follow the same disease progression as fat infiltration 13, 34 ; instead, T2 of muscle water appears to be highest in earlier stages of the disease. 15 In a study on corticosteroid therapy followup in young patients with DMD with very low fat infiltration, 35 investigators used NMRI and 1 H NMRS to measure fat fraction and T2 of water with the 6MWT, timed tests, and quantitative force measurements of the lower limb. Though no direct comparison was given, the 6MWT did not discriminate between treated and untreated patients, nor did plantar flexion strength. In contrast, timed tests, knee extension strength, %F, and water T2 all discriminated between treated and untreated patients. Moreover, investigators observed reduced T2 after 3 months of therapy, suggesting reduced inflammation, with differences in %F only after 1 year.
Spectroscopy findings in the upper limbs also reproduced previous findings in lower limb studies, 7,37-40 such as the reduction in PCr/ATP related to loss of functional muscle tissue, the increase in membrane metabolite phosphomonoesters and phosphodiesters related to membrane disruption, and the increase in diesters possibly related to preferential glycolytic fiber destruction. Additionally, we report an increased level of Pib, presumably an anomalous pool of Pi, with poor pH regulation. 25 The Pib/Pi pool increases, as does average pH, with disease progression, whereas Pia/PCr increases as cell energy wasting increases. We also propose an arbitrary but sensitive to disease progression index for PDE/PCr that combines PDE/ATP and PCr/ATP, which respectively increases and decreases with disease progression. 21 All metabolic indices correlated with functional measurements and deteriorated as strength and function diminished, though possibly not linearly.
Overall, even though all variables except the Mo-viPlate score strongly discriminated between ambulatory and nonambulatory patients, none of the upper limb clinical assessments showed marked progression over 1 year in the subgroup of ambulatory patients. Contrary to what has been described previously in a similar population, the change in MFM over 1 year did not achieve significance (p 5 0.058). This is possibly related to the limited number of patients in the study. In NMR indices, there was no difference over 1 year in upper limbs of ambulatory patients. Despite the excellent correlations between NMR and functional measures at baseline, there were almost no correlations in how measures for individual patients evolved over 1 year. This was not surprising as none of the patients changed dramatically over the course of the year and the nonlinear associations observed suggest that whereas some variables in an individual may change, others may not, depending on his clinical status.
Despite slow progression, the metabolic NMRS indices, the %F, and the distal strength of patients with DMD were initially abnormal compared to age-matched healthy children. 21 Some variables (grip and pinch strength, %F, and Pib/Pi) demonstrated a 1-year change in nonambulatory patients and are thus good comparators for this population. Outcome measures are often presented as competing, but here we aimed to show complementarity. Correlation of the variables is somewhat dependent on clinical status. This is hardly surprising, given the very different nature of measured outcomes, ranging from strength to cellular metabolism. For instance, grip strength is clearly more sensitive to change in PDE/ATP when grip strength is higher than approximately 4 kg, but the opposite holds true when the patient becomes weaker. In addition, combining approaches may help to better understand performance of apparent outliers and to validate a measure that may appear to be false. This is illustrated in this study by the patient who clearly outperformed peers in distal strength, but presented as normal when related to NMR indices.
Thus, the question of how a single outcome is clinically meaningful alone is probably less important than the question of how several outcomes can depict the changes experienced by the patients in a complementary way in order to conveniently describe the evolution of pathophysiologic features and clinical status throughout life. Correct choice and stratification of outcome measures in primary, secondary, or tertiary outcomes in nonambulatory patients should take into account the stage of the disease. In nonambulatory patients with early stage DMD, grip and pinch strength combined with T2 measures could constitute a good choice. Percentage of fat in the upper limb muscles is useful throughout the late ambulatory and the nonambulatory period, as it appeared to highly correlate with functional assessments in these patients. 
